Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Gene Maps to Navigate Future Cancer Research

By Drug Discovery Trends Editor | September 10, 2008

Three epic studies, separately published in the September 4, 2008 issues of Science and Nature, aimed to improve our understanding of cancer genetics.

One of these studies, published in Nature, was conducted by The Cancer Genome Atlas (TCGA) Research Network, a collaborative effort funded by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), reported on the discovery of new genetic mutations in the most common form of brain cancer, glioblastoma multiforme (GBM). In this study, TCGA identified three previously unrecognized, high frequency mutations in GBM tumors, delineated core cell signaling pathways that are disrupted in GBM, and stumbled upon a potential resistance mechanism to a common chemotherapy used in brain cancer patients. The three previously unknown gene mutations were uncovered during the sequencing of 601 genes in GBM samples and matched control tissue. And these three mutations fell into three genes previously associated with uncontrolled tissue growth: NF1, ERBB2, and PIK3R1, the latter of which is a regulator of PI3K, a frequent target of cancer chemotherapy. By combining sequencing data with gene expression and DNA methylation patterns, the TCGA researchers were also able to delineate core biological pathways (CDK/cyclin/CDK inhibitor/RB, p53, and the RTK/RAS/PI3K pathways), which they found to be disrupted in GBM tumors, suggesting potential involvement in GBM pathogenesis. This study created the first gene map of GBM.

In other news, two separate studies published in Science in September 2008 reported on gene maps of GBM and pancreatic cancer. The studies represented a massive collaboration between the Johns Hopkins Kimmel Cancer Center, Duke University, and other research centers, in which 20,661 genes were sequenced from 24 patients with pancreatic cancer and 22 patients with glioblastoma. Every one of these tumors had a different set of profiles, further confounding the issue of “personalized” therapy. However, when the hundreds of cancer-associated mutations identified in these studies were examine more closely, many could be assigned to specific cell signaling pathways. For example, the researchers identified 12 core aberrant signaling pathways in pancreatic tumors, some of which were involved in either apoptosis or DNA repair—the disruption of which has been shown to lead to other forms of cancer.

“This perspective changes the way we think about solid tumors and their management, because drugs or other agents that target the physiologic effects of these pathways, rather than individual gene components, are likely to be the most useful approach for developing new therapies,” says Bert Vogelstein, MD, co-director of the Ludwig Center at Johns Hopkins and a Howard Hughes Medical Institute investigator.

Additionally, seventy genes identified in this study were found to be overexpressed on the tumor cell surface or in overexpressed in tumor secretions, increasing their potential as biomarkers in screening or diagnostic tests.

The significance of these studies has yet to be realized, but a greater systems approach to cancer drug design, whereby pathways and not individual proteins are targeted, would be a step in the right direction.

Release date: September 4, 2008
Sources:
The Cancer Genome Atlas Research Network
Howard Hughes Medical Insitute
Johns Hopkins Kimmel Cancer Center


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE